Patent intelligence · US
US 11919868
Heterocyclic compounds and related methods
Heterocyclic compounds and related methods
Patent details — US 11919868
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 5, 2024
- Expiration
- Feb 29, 2044
- Applicant
- Recursion Pharmaceuticals, Inc.
- Claims
- 24
- CPC classes
- A61P, A61P31/04
Quick answer
US 11919868 (Heterocyclic compounds and related methods) is held by Recursion Pharmaceuticals, Inc.. Status: granted. Granted Mar 5, 2024. Expires Feb 29, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Recursion Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 24
- CPC classes
- A61P, A61P31/04
More from Recursion Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 11033494
Apparatuses containing an emulsion and methods of manufacture
granted -
US 6331564
Use of triaryl methane compounds for inhibiting unwanted cellular proliferation associated with inflammatory disease
expired -
US 6028103
Triaryl methane compounds and analogues thereof useful for the treatment or prevention of sickle cell disease or diseases characterized by abnormal cell proliferation
expired
Frequently asked questions
What is US patent 11919868?
US 11919868 (Heterocyclic compounds and related methods) is held by Recursion Pharmaceuticals, Inc.. Status: granted. Granted Mar 5, 2024. Expires Feb 29, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11919868?
Recursion Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 4 pharmaceutical patents for this assignee.
When does US 11919868 expire?
Our index shows an expiration date of Feb 29, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.